CO-OPTIV-SECURIT
10.6.2019 15:07:06 CEST | Business Wire | Press release
Optiv Security , a global cybersecurity integrator delivering end-to-end cybersecurity solutions, today announced it has been recognized by Forrester Research as a Strong Performer in The Forrester WaveTM : Global Cybersecurity Consulting Providers, Q2 2019. The report identifies Optiv as having received the highest possible score for six criteria:
- Delivery and engagement innovation
- IP and asset-based consulting
- Technical consulting and assessment capabilities
- Cybersecurity focus
- Go-to-market strategy
- Partnership ecosystems
“Optiv’s approach to cybersecurity is aligned to new business models and centered on driving client-focused outcomes. It is designed to optimize and rationalize existing cybersecurity programs, build new integrated, end to end cybersecurity programs, and help clients transform how they are consuming and applying cybersecurity,” said Bryan Wiese, division vice president, global advisory services for Optiv.
“We believe that receiving this designation from Forrester as a Strong Performer affirms our approach to consulting for global enterprises,” continued Wiese. “Historically, the fear of external threats and vulnerabilities has often guided clients’ security initiatives. That fear has sometimes led to tactical investment, too much of a focus on technology, and siloed problem solving. At Optiv we work with clients to manage their security programs from the ‘inside-out,’ starting with risk mitigation and building from there with customized strategy, focused process definition, technology rationalization and operations optimization, ongoing measurement and communication. Our approach is specifically designed to deliver to organizations integrated cybersecurity solutions that address the speed of business change by providing new consumption and outcome-based consulting services and cybersecurity solutions. Our goal is help clients strike the right balance between risk mitigation, business alignment, and cost.”
Optiv’s full suite of advisory services can be consumed alone or combined with Optiv’s integration or managed services, or Cyber-as-a-Service (CaaSTM ) platform to harden security fundamentals across six main domains:
- Risk Management and Transformation – Optiv enables clients to address risk and regulatory changes with an inside-out strategy that begins with business needs and applies strategy, technology and processes to effectively manage risk and enable cyber resilience.
- Cyber Operations – Optiv helps clients strike the right balance of people, process, technologies and delivery methods in order to elevate threat preparedness while aligning business goals and operational resilience and producing measurable outcomes at reduced operational costs.
- Cyber Digital Transformation – Optiv aligns client business needs with a security-by-design approach that employs big data analytics, IoT, cloud, orchestration and automation and additional technology innovations to connect agile processes and controls.
- Identity and Data Management – Optiv helps clients tackle identity and data sprawl and exposure with comprehensive, strategic identity and data management solutions. Enabling organizations to quickly and securely provide access to the right company assets on- and off-premise ensures trust and compliance in the business while also strengthening security by classifying, governing and protecting sensitive data.
- Threat Management – Proactively solving threat management requires a comprehensive program that includes tracking technological and regulatory changes, driving security into network design and software development lifecycles, continual threat modeling, testing and remediation, an understanding of the attack surface, and readiness exercises to practice muscle memory and robust response should an incident occur.
Please visit Optiv’s website to learn more about Optiv’s cybersecurity consulting services .
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: www.youtube.com/c/OptivInc
Blog: www.optiv.com/explore-optiv-insights/blog
About Optiv Security
Optiv is a global cybersecurity
solutions integrator – a “one-stop” trusted partner with a singular
focus on cybersecurity. Our end-to-end cybersecurity capabilities span
risk management and transformation, cyber digital transformation, threat
management, cyber operations, identity and data management, and
integration and innovation, helping organizations realize stronger,
simpler and more cost-efficient cybersecurity programs that support
business requirements and outcomes. At Optiv, we are modernizing
cybersecurity to enable clients to innovate their consumption models,
integrate infrastructure and technology to maximize value, achieve
measurable outcomes, and realize complete solutions and business
alignment. For more information about Optiv, please visit us at www.optiv.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005093/en/
Contact:
Brett Ater (913) 304-7683 brett.ater@optiv.com or Jason Cook (816) 701-3374 jason.cook@optiv.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
